Rational Approaches to the Design of Therapeutics Targeting Molecular Markers: The Case of Chronic Myelogenous Leukemia

@article{Saglio2004RationalAT,
  title={Rational Approaches to the Design of Therapeutics Targeting Molecular Markers: The Case of Chronic Myelogenous Leukemia},
  author={G. Saglio and A. Morotti and G. Mattioli and E. Messa and E. Giugliano and G. Volpe and G. Rege-Cambrin and D. Cilloni},
  journal={Annals of the New York Academy of Sciences},
  year={2004},
  volume={1028}
}
  • G. Saglio, A. Morotti, +5 authors D. Cilloni
  • Published 2004
  • Biology, Medicine
  • Annals of the New York Academy of Sciences
    • Abstract: Progress in understanding the molecular basis of signal transmission and transduction has contributed substantially to clarifying the mechanisms of leukemogenesis and of leukemia progression and has led to the identification of a number of specific molecular targets for treatment. Chronic myeloid leukemia (CML) has provided one of the best models, as the identification of a leukemia‐specific hybrid tyrosine kinase (BCR‐ABL, p210, p190) has led to the identification and the successful… CONTINUE READING
    View on Wiley
    ncbi.nlm.nih.gov
    26 Citations
    Highly Influential Citations
    1
    Background Citations
    7
    26 Citations
    Citation Type

    Citation Type

    Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
    • 3
    • PDF
    Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
    • 6
    • PDF
    The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias
    • 13
    • PDF
    BLCTT_A_228815 45..52
    Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion
    • 17
    • PDF
    Role of Methylenetetrahydrofolate Reductase (Mthfr), Glutathione S-transferases (Gsts M1 and T1) and Haptoglobin (Hp) Gene Polymorphisms in Susceptibility to Chronic Myeloid Leukemia (Cml)
    • 11
    • Highly Influenced
    Perturbations of TGF-β Signaling in Leukocytes as Drivers of Leukemogenesis and Epithelial Tumorigenesis
    A Case Report of Personalized Chemotherapy for Metastatic Cardiac Sarcoma
    Cytogenetic investigation in chronic myeloid leukemia: study from an Indian population.
    • 14
    Potential use of nucleic acid-based agents in the sensitization of nasopharyngeal carcinoma to radiotherapy.
    • 21

    References

    SHOWING 1-10 OF 45 REFERENCES
    The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
    • 730
    • PDF
    Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    • 4,763
    • PDF
    Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
    • 557
    • PDF
    Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
    • 23
    Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
    • 3,007
    • PDF
    Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    • 453
    Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
    • 89
    • PDF
    The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
    • 185
    • PDF
    Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    • 2,664
    • PDF
    Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
    • 353